For the year ending 2025-12-31, ANTX had -$1,410K decrease in cash & cash equivalents over the period.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -35,174 |
| Stock-based compensation expense | 6,246 |
| Net accretion of discount on investments | 1,070 |
| Prepaid expenses and other assets | -1,512 |
| Accounts payable | -296 |
| Accrued compensation | 742 |
| Accrued liabilities | -2,402 |
| Other current liabilities | 438 |
| Other non-current liabilities | 170 |
| Net cash used in operating activities | -29,834 |
| Purchases of investments | 46,189 |
| Maturities of investments | 74,500 |
| Net cash provided by investing activities | 28,311 |
| Proceeds from issuance of common stock under the espp | 86 |
| Proceeds from exercise of stock options | 27 |
| Net cash provided by financing activities | 113 |
| Net (decrease) increase in cash and cash equivalents | -1,410 |
| Cash and cash equivalents at the beginning of the period | 21,351 |
| Cash and cash equivalents at the end of the period | 19,941 |
AN2 Therapeutics, Inc. (ANTX)
AN2 Therapeutics, Inc. (ANTX)